Acute kidney injury: Difference between revisions

Jump to navigation Jump to search
Line 13: Line 13:
{| class="wikitable" style="float:center; text-align:center"
{| class="wikitable" style="float:center; text-align:center"
|+ RIFLE criteria to define acute kidney injury (AKI)
|+ RIFLE criteria to define acute kidney injury (AKI)
! Type !! bgcolor="#d9ff54" ! U<sub>Osm</sub> !! U<sub>Na</sub> !! Fe<sub>Na</sub> !! [[BUN-to-creatinine ratio|BUN/Cr]]
! bgcolor="#d9ff54"!Type !! U<sub>Osm</sub> !! U<sub>Na</sub> !! Fe<sub>Na</sub> !! [[BUN-to-creatinine ratio|BUN/Cr]]
|-
|-
| Prerenal || >500 || <10 || <1% || >20
| Prerenal || >500 || <10 || <1% || >20

Revision as of 21:30, 18 October 2013

WikiDoc Resources for Acute kidney injury

Articles

Most recent articles on Acute kidney injury

Most cited articles on Acute kidney injury

Review articles on Acute kidney injury

Articles on Acute kidney injury in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Acute kidney injury

Images of Acute kidney injury

Photos of Acute kidney injury

Podcasts & MP3s on Acute kidney injury

Videos on Acute kidney injury

Evidence Based Medicine

Cochrane Collaboration on Acute kidney injury

Bandolier on Acute kidney injury

TRIP on Acute kidney injury

Clinical Trials

Ongoing Trials on Acute kidney injury at Clinical Trials.gov

Trial results on Acute kidney injury

Clinical Trials on Acute kidney injury at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acute kidney injury

NICE Guidance on Acute kidney injury

NHS PRODIGY Guidance

FDA on Acute kidney injury

CDC on Acute kidney injury

Books

Books on Acute kidney injury

News

Acute kidney injury in the news

Be alerted to news on Acute kidney injury

News trends on Acute kidney injury

Commentary

Blogs on Acute kidney injury

Definitions

Definitions of Acute kidney injury

Patient Resources / Community

Patient resources on Acute kidney injury

Discussion groups on Acute kidney injury

Patient Handouts on Acute kidney injury

Directions to Hospitals Treating Acute kidney injury

Risk calculators and risk factors for Acute kidney injury

Healthcare Provider Resources

Symptoms of Acute kidney injury

Causes & Risk Factors for Acute kidney injury

Diagnostic studies for Acute kidney injury

Treatment of Acute kidney injury

Continuing Medical Education (CME)

CME Programs on Acute kidney injury

International

Acute kidney injury en Espanol

Acute kidney injury en Francais

Business

Acute kidney injury in the Marketplace

Patents on Acute kidney injury

Experimental / Informatics

List of terms related to Acute kidney injury

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Acute kidney failure; acute renal failure; acute uremia; AKI; ARF

Overview

Acute kidney injury (AKI), formerly known as acute renal failure, is characterized by an abrupt loss of kidney function resulting in a failure to excrete nitrogenous waste products (among others), and a disruption of fluid and electrolyte homeostasis. AKI defines a spectrum of disease with common clinical features including an increase in the serum creatinine and BUN levels, often associated with a reduction in urine volume. AKI can be caused by a multitude of factors broadly categorized into pre-renal (usually ischemic), intrinsic renal (usually toxic), and post-renal (usually obstructive) injuries. Generally, treatment is supportive until renal function is restored especially in light of the fluid overload, electrolyte imbalances, and uremic toxin accumulation. Still, renal replacement modalities are sometimes indicated.

Definition

Over 30 different definitions of AKI have been used in the literature since it was first described, which prompted the need for a uniform definition. In 2004, The Acute Dialysis Quality Initiative (ADQI) proposed the first consensus definition known as the RIFLE criteria. The acronym combines a classification of 3 levels of renal dysfunction (Risk, Injury, Failure) with 2 clinical outcomes (Loss, ESRD). This unified classification was proposed to enable a viable comparison in trials of prevention and therapy and to observe clinical outcomes of the defined stages of AKI.

RIFLE criteria to define acute kidney injury (AKI)
bgcolor="#d9ff54"!Type UOsm UNa FeNa BUN/Cr
Prerenal >500 <10 <1% >20
Intrinsic <350 >20 >2% <15[citation needed]
Postrenal <350 >40 >4% >15

In 2007, the Acute Kidney Injury Network (AKIN) proposed a modified diagnostic criteria based on the RIFLE criteria. AKI was defined as an acute increase in the serum creatinine of ≥0.3 mg/dL from baseline within 48 hours, a 50% increase in the serum creatinine concentration, or oliguria <0.5 mL/kg/h for 6 hours (following volume status optimization). The staging criteria retained the Risk, Injury, & Failure stages from the RIFLE criteria, with modifications related to serum creatinine increase.

Classic laboratory findings in AKI
Type UOsm UNa FeNa BUN/Cr
Prerenal >500 <10 <1% >20
Intrinsic <350 >20 >2% <15[citation needed]
Postrenal <350 >40 >4% >15

In March 2012, the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Acute Kidney Injury retained the AKIN staging criteria while implementing modifications to the definition of AKI. They developed definition and staging criteria for AKI that combined previous definitions into a more clinically applicable one. AKI was defined as either:

  • an increase in serum creatinine by 0.3 mg/dL in 48 hours
  • an increase in serum creatinine by more than 50% of baseline or 1.5 times baseline occuring in the past 7 days
  • a decrease in urine volume <0.5 mL/kg/h for 6 hours

Historical Perspective

It is really unclear when acute kidney injury or acute renal failure came to light as a separate disease entity. The first documented report of abrupt loss of renal function came from Beall et al in 1941 who described a man admitted to St. Thomas's Hospital after a crush injury to the leg in a bombing incident. They describe a course of rapidly progressive renal insufficiency with dark urine, edema, elevated potassium levels, and disorientation. [1]

The earliest definition came from Lucké in 1946 who described the histologic pathology we now know as acute tubular necrosis. The term lower nephron nephrosis was introduced and was later used to refer to abrupt renal failure secondary to excessive vomiting, thermal burns, crush injuries, hemolysis, and obstructive prostate disease.[2][3] The term slowly drifted to become acute renal failure to depict a clinical syndrome rather than a pathologic finding. Acute renal failure was then replaced by acute kidney injury in 2006 following a consensus that even minor changes in serum creatinine not necessarily overt failure can lead to significant changes in outcome.

Classification

Acute kidney injury is diagnosed on the basis of clinical history and laboratory data. A diagnosis is made when there is rapid reduction in kidney function, as measured by serum creatinine, or based on a rapid reduction in urine output, termed oliguria.

Definition

Introduced by the Acute Kidney Injury Network (AKIN), specific criteria exist for the diagnosis of AKI:[4]

  1. Rapid time course (less than 48 hours)
  2. Reduction of kidney function
    • Rise in serum creatinine, defined by either:
      • Absolute increase in serum creatinine of ≥0.3 mg/dl (≥26.4 μmol/l)
      • Percentage increase in serum creatinine of ≥50%
    • Reduction in urine output, defined as <0.5 ml/kg/hr for more than 6 hours

Staging

The RIFLE criteria, proposed by the Acute Dialysis Quality Initiative (ADQI) group, aid in the staging of patients with AKI:[5][6]

  • Risk: GFR decrease >25%, serum creatinine increased 1.5 times or urine production of <0.5 ml/kg/hr for 6 hours
  • Injury: GFR decrease >50%, doubling of creatinine or urine production <0.5 ml/kg/hr for 12 hours
  • Failure: GFR decrease >75%, tripling of creatinine or creatinine >355 μmol/l (with a rise of >44) (>4 mg/dl) OR urine output below 0.3 ml/kg/hr for 24 hours
  • Loss: persistent AKI or complete loss of kidney function for more than 4 weeks
  • End-stage renal disease: need for renal replacement therapy (RRT) for more than 3 months

Pathophysiology

Causes

AKI can be caused by disease, crush injury, contrast agents, some antibiotics, and more.

The causes of acute kidney injury are commonly categorized into prerenal, intrinsic, and postrenal.

Classic laboratory findings in AKI
Type UOsm UNa FeNa BUN/Cr
Prerenal >500 <10 <1% >20
Intrinsic <350 >20 >2% <15[citation needed]
Postrenal <350 >40 >4% >15

Prerenal

Prerenal causes of AKI ("pre-renal azotemia") are those that decrease effective blood flow to the kidney. These include systemic causes, such as low blood volume, low blood pressure, heart failure, and local changes to the blood vessels supplying the kidney. The latter include renal artery stenosis, or the narrowing of the renal artery which supplies the kidney with blood, and renal vein thrombosis, which is the formation of a blood clot in the renal vein that drains blood from the kidney.

Renal ischaemia ultimately results in functional disorder, depression of GFR, or both. These causes stem from the inadequate cardiac output and hypovolemia or vascular diseases causing reduced perfusion of both kidneys. Both kidneys need to be affected as one kidney is still more than adequate for normal kidney function.

Intrinsic

Sources of damage to the kidney itself are dubbed intrinsic. Intrinsic AKI can be due to damage to the glomeruli, renal tubules, or interstitium. Common causes of each are glomerulonephritis, acute tubular necrosis (ATN), and acute interstitial nephritis (AIN), respectively. A cause of intrinsic acute renal failure is tumor lysis syndrome.[7]

Postrenal

Postrenal AKI is a consequence of urinary tract obstruction. This may be related to benign prostatic hyperplasia, kidney stones, obstructed urinary catheter, bladder stone, bladder, ureteral or renal malignancy. It is useful to perform a bladder scan or a post void residual to rule out urinary retention. In post void residual, a catheter is inserted immediately after urinating to measure fluid still in the bladder. 50-100ml suggests neurogenic bladder. A renal ultrasound will demonstrate hydronephrosis if present. A CT scan of the abdomen will also demonstrate bladder distension or hydronephrosis, however, in case of acute renal failure, the use of IV contrast is contraindicated. On the basic metabolic panel, the ratio of BUN to creatinine may indicate post renal failure.

Epidemiology

New cases of AKI are unusual but not rare, affecting approximately 0.1% of the UK population per year (2000 ppm/year), 20x incidence of new ESRD. AKI requiring dialysis (10% of these) is rare (200 ppm/year), 2x incidence of new ESRD.[8]

Acute kidney injury is common among hospitalized patients. It affects some 3-7% of patients admitted to the hospital and approximately 25-30% of patients in the intensive care unit.[9]

Risk Factors

Natural History

Complications

Metabolic acidosis, hyperkalemia, and pulmonary edema may require medical treatment with sodium bicarbonate, antihyperkalemic measures, and diuretics.

Lack of improvement with fluid resuscitation, therapy-resistant hyperkalemia, metabolic acidosis, or fluid overload may necessitate artificial support in the form of dialysis or hemofiltration.[10]

Prognosis

Depending on the cause, a proportion of patients will never regain full renal function, thus entering end-stage renal failure and requiring lifelong dialysis or a kidney transplant. Patients with AKI are more likely to die prematurely after they were discharged from hospital even if their kidney function has recovered.[11]

Diagnosis

Signs and symptoms

The symptoms of acute kidney injury result from the various disturbances of kidney function that are associated with the disease. Accumulation of urea and other nitrogen-containing substances in the bloodstream lead to a number of symptoms, such as fatigue, loss of appetite, headache, nausea and vomiting.[12] Marked increases in the potassium level can lead to irregularities in the heartbeat, which can be severe and life-threatening.[10] Fluid balance is frequently affected, though hypertension is rare.[13]

Pain in the flanks may be encountered in some conditions (such as thrombosis of the renal blood vessels or inflammation of the kidney); this is the result of stretching of the fibrous tissue capsule surrounding the kidney.[14] If the kidney injury is the result of dehydration, there may be thirst as well as evidence of fluid depletion on physical examination.[14] Physical examination may also provide other clues as to the underlying cause of the kidney problem, such as a rash in interstitial nephritis and a palpable bladder.[14]

Inability to excrete sufficient fluid from the body can cause accumulation of fluid in the limbs (peripheral edema) and the lungs (pulmonary edema),[12] as well as cardiac tamponade as a result of fluid effusions.[13]

Detection

The deterioration of renal function may be discovered by a measured decrease in urine output. Often, it is diagnosed on the basis of blood tests for substances normally eliminated by the kidney: urea and creatinine. Both tests have their disadvantages. For instance, it takes about 24 hours for the creatinine level to rise, even if both kidneys have ceased to function. A number of alternative markers has been proposed (such as NGAL, KIM-1, IL18 and cystatin C), but none are currently established enough to replace creatinine as a marker of renal function.[citation needed][when?]

Sodium and potassium, two electrolytes that are commonly deranged in people with acute kidney injury, are typically measured together with urea and creatinine.[citation needed]

Further testing

Once the diagnosis of AKI is made, further testing is often required to determine the underlying cause. These may include urine sediment analysis, renal ultrasound and/or kidney biopsy. Indications for renal biopsy in the setting of AKI include:[15]

  1. Unexplained AKI
  2. AKI in the presence of the nephritic syndrome
  3. Systemic disease associated with AKI

Treatment

The management of AKI hinges on identification and treatment of the underlying cause. In addition to treatment of the underlying disorder, management of AKI routinely includes the avoidance of substances that are toxic to the kidneys, called nephrotoxins. These include NSAIDs such as ibuprofen, iodinated contrasts such as those used for CT scans, many antibiotics such as gentamicin, and a range of other substances.[16]

Monitoring of renal function, by serial serum creatinine measurements and monitoring of urine output, is routinely performed. In the hospital, insertion of a urinary catheter helps monitor urine output and relieves possible bladder outlet obstruction, such as with an enlarged prostate.

Specific therapies

In prerenal AKI without fluid overload, administration of intravenous fluids is typically the first step to improve renal function. Volume status may be monitored with the use of a central venous catheter to avoid over- or under-replacement of fluid.

Should low blood pressure prove a persistent problem in the fluid-replete patient, inotropes such as norepinephrine and dobutamine may be given to improve cardiac output and hence renal perfusion. While a useful pressor, there is no evidence to suggest that dopamine is of any specific benefit,[17] and may be harmful.

The myriad causes of intrinsic AKI require specific therapies. For example, intrinsic AKI due to Wegener's granulomatosis may respond to steroid medication. Toxin-induced prerenal AKI often responds to discontinuation of the offending agent, such as aminoglycoside, penicillin, NSAIDs, or paracetamol.[14]

If the cause is obstruction of the urinary tract, relief of the obstruction (with a nephrostomy or urinary catheter) may be necessary.

Diuretic agents

The use of diuretics such as furosemide, is widespread and sometimes convenient in ameliorating fluid overload, and is not associated with higher mortality (risk of death).[18]

Renal replacement therapy

Renal replacement therapy, such as with hemodialysis, may be instituted in some cases of AKI. A systematic review of the literature in 2008 demonstrated no difference in outcomes between the use of intermittent hemodialysis and continuous venovenous hemofiltration (CVVH).[19] Among critically ill patients, intensive renal replacement therapy with CVVH does not appear to improve outcomes compared to less intensive intermittent hemodialysis.[16][20]

See also

Related Chapters

Acute Renal Failure Videos

Acute Renal Failure 1

{{#ev:youtube|cPIk7iLMwOI}}

Acute Renal Failure 2

{{#ev:youtube|MmQKGeAyUOM}}

Acute Renal Failure 3

{{#ev:youtube|8IU0ABdvCQA}}

Acute Renal Failure 4

{{#ev:youtube|VxzIE6npBTk}}

Acute Renal Failure 5

{{#ev:youtube|IyLC9b1Bilc}}

References

  1. Beall D, Bywaters EG, Belsey RH, Miles JA (1941). "Crush Injury with Renal Failure". Br Med J. 1 (4185): 432–4. PMC 2161708. PMID 20783578‎ Check |pmid= value (help).
  2. LUCKE B (1946). "Lower nephron nephrosis; the renal lesions of the crush syndrome, of burns, transfusions, and other conditions affecting the lower segments of the nephrons". Mil Surg. 99 (5): 371–96. PMID 20276793.
  3. STRAUSS MB (1948). "Acute renal insufficiency due to lower-nephron nephrosis". N Engl J Med. 239 (19): 693–700. doi:10.1056/NEJM194811042391901. PMID 18892579.
  4. Mehta RL, Kellum JA, Shah SV; et al. (2007). "Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury". Critical Care (London, England). 11 (2): R31. doi:10.1186/cc5713. PMC 2206446. PMID 17331245.
  5. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004). "Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group". Crit Care. 8 (4): R204–12. doi:10.1186/cc2872. PMC 522841. PMID 15312219.
  6. Lameire N, Van Biesen W, Vanholder R (2005). "Acute renal failure". Lancet. 365 (9457): 417–30. doi:10.1016/S0140-6736(05)17831-3. PMID 15680458.
  7. Jim Cassidy, Donald Bissett, Roy A. J. Spence, Miranda Payne (1 January 2010). Oxford Handbook of Oncology. Oxford University Press. p. 706.
  8. "Renal Medicine: Acute Kidney Injury (AKI)". Renalmed.co.uk. 2012-05-23. Retrieved 2013-07-17.
  9. Brenner and Rector's The Kidney. Philadelphia: Saunders. 2007. ISBN 1-4160-3110-3.
  10. 10.0 10.1 Weisberg LS (2008). "Management of severe hyperkalemia". Crit. Care Med. 36 (12): 3246–51. doi:10.1097/CCM.0b013e31818f222b. PMID 18936701. Unknown parameter |month= ignored (help)
  11. 12.0 12.1 Skorecki K, Green J, Brenner BM (2005). "Chronic renal failure". In Kasper DL, Braunwald E, Fauci AS; et al. Harrison's Principles of Internal Medicine (16th ed.). New York, NY: McGraw-Hill. pp. 1653–63. ISBN 0-07-139140-1.
  12. 13.0 13.1 Tierney, Lawrence M. (2004). "22". CURRENT Medical Diagnosis and Treatment 2005 (44 ed.). McGraw-Hill. p. 871. ISBN 0-07-143692-8. Unknown parameter |coauthors= ignored (help); |access-date= requires |url= (help)
  13. 14.0 14.1 14.2 14.3 Brady HR, Brenner BM (2005). "Chronic renal failure". In Kasper DL, Braunwald E, Fauci AS; et al. Harrison's Principles of Internal Medicine (16th ed.). New York, NY: McGraw-Hill. pp. 1644–53. ISBN 0-07-139140-1.
  14. Papadakis MA, McPhee SJ (2008). Current Medical Diagnosis and Treatment. McGraw-Hill Professional. ISBN 0-07-159124-9.
  15. 16.0 16.1 Palevsky PM, Zhang JH, O'Connor TZ; et al. (2008). "Intensity of renal support in critically ill patients with acute kidney injury". The New England Journal of Medicine. 359 (1): 7–20. doi:10.1056/NEJMoa0802639. PMC 2574780. PMID 18492867. Unknown parameter |month= ignored (help)
  16. Holmes CL, Walley KR (2003). "Bad medicine: low-dose dopamine in the ICU". Chest. 123 (4): 1266–75. doi:10.1378/chest.123.4.1266. PMID 12684320.
  17. Uchino S, Doig GS, Bellomo R; et al. (2004). "Diuretics and mortality in acute renal failure". Crit. Care Med. 32 (8): 1669–77. doi:10.1097/01.CCM.0000132892.51063.2F. PMID 15286542.
  18. Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M (2008). "Renal replacement therapy in patients with acute renal failure: a systematic review". JAMA : the Journal of the American Medical Association. 299 (7): 793–805. doi:10.1001/jama.299.7.793. PMID 18285591. Unknown parameter |month= ignored (help)
  19. Bellomo R, Cass A, Cole L; et al. (2009). "Intensity of continuous renal-replacement therapy in critically ill patients". The New England Journal of Medicine. 361 (17): 1627–38. doi:10.1056/NEJMoa0902413. PMID 19846848. Unknown parameter |month= ignored (help)

Template:Nephrology Template:Organ failure

Template:WH Template:WS